Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

C0450000

Carbamazepin

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

5H-Dibenz[b,f]azepin-5-carboxamid

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C15H12N2O
CAS-Nummer:
298-46-4
Molekulargewicht:
236.27
MDL-Nummer:
MFCD00005073
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329774792
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

carbamazepine

Hersteller/Markenname

EDQM

mp (Schmelzpunkt)

191-192 °C (lit.)

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

NC(=O)N1c2ccccc2C=Cc3ccccc13

InChI

1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)

InChIKey

FFGPTBGBLSHEPO-UHFFFAOYSA-N

Angaben zum Gen

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Carbamazepine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem./physiol. Wirkung

Antikonvulsivum; Ligand für die Benzodiazepin modulatorische Stelle am GABAA-Rezeptor; Natriumkanalinhibitor.

Verpackung

Dieses Produkt wird, wie von der entsprechenden Pharmakopöe geliefert, angeboten. Die aktuellen Mengeneinheiten finden Sie im Referenzsubstanzen-Katalog der EDQM.

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

1093001

Carbamazepin, United States Pharmacopeia (USP) Reference Standard

Y0000033

Carbamazepin Unreinheit A, European Pharmacopoeia (EP) Reference Standard

PHR1197

Iminostilben, Pharmaceutical Secondary Standard; Certified Reference Material

1093023

Carbamazepin-verwandte Verbindung B, United States Pharmacopeia (USP) Reference Standard

1093012

Carbamazepin-verwandte Verbindung A, United States Pharmacopeia (USP) Reference Standard

1424084

9-Methylacridin, United States Pharmacopeia (USP) Reference Standard

BP974

Carbamazepin, British Pharmacopoeia (BP) Reference Standard

PHR1918

Carbamazepin-verwandte Verbindung A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2433

Carbamazepin-Unreinheit F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2330

Carbamazepine Impurity C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2237

Carbamazepin-Unreinheit B, pharmaceutical secondary standard, certified reference material

Piktogramme

Health hazardExclamation mark
GHS08,GHS07

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 4 Oral - Repr. 1A - Resp. Sens. 1 - Skin Sens. 1A - STOT SE 3

Zielorgane

Central nervous system

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Ursula Amstutz et al.
Epilepsia, 55(4), 496-506 (2014-03-07)
To systematically review evidence on genetic risk factors for carbamazepine (CBZ)-induced hypersensitivity reactions (HSRs) and provide practice recommendations addressing the key questions: (1) Should genetic testing for HLA-B*15:02 and HLA-A*31:01 be performed in patients with an indication for CBZ therapy
V L Yip et al.
Clinical pharmacology and therapeutics, 92(6), 757-765 (2012-11-08)
Carbamazepine (CBZ) therapy is associated with cutaneous adverse reactions in up to 10% of patients. Predisposition to these hypersensitivity reactions has been linked to the human leukocyte antigen (HLA) genotype. This systematic review determines the strength of these associations and
Janneke Jentink et al.
BMJ (Clinical research ed.), 341, c6581-c6581 (2010-12-04)
To identify specific major congenital malformations associated with use of carbamazepine in the first trimester of pregnancy. A review of all published cohort studies to identify key indications and a population based case-control study to test these indications. Review of
Sandeep Grover et al.
Pharmacogenetics and genomics, 24(2), 94-112 (2013-12-18)
A considerable heterogeneity exists in the literature on the role of different HLA alleles in carbamazepine (CBZ)-induced cutaneous adverse drug reactions (cADRs) of varying severity among diverse ethnic groups. The aim of the present study was to understand and summarize
Robert J Hatch et al.
Epilepsia, 55(4), 601-608 (2014-03-13)
A NaV β1(C121W) mouse model of human genetic epilepsy has enhanced neuronal excitability and temperature sensitivity attributed to a decreased threshold for action potential firing in the axon initial segment. To investigate the network consequences of this neuronal dysfunction and
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.